Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1093/qjmed/hcv181

http://scihub22266oqcxt.onion/10.1093/qjmed/hcv181
suck pdf from google scholar
C4900488!4900488 !26428335
unlimited free pdf from europmc26428335
    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26428335 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid26428335
      QJM 2016 ; 109 (6 ): 367-72
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Clinical development of cancer therapeutics that target metabolism #MMPMID26428335
  • Clem BF ; O'Neal J ; Klarer AC ; Telang S ; Chesney J
  • QJM 2016[Jun]; 109 (6 ): 367-72 PMID26428335 show ga
  • Glucose and glutamine metabolism in cancer cells are markedly elevated relative to non-transformed normal cells. This metabolic reprogramming enables the production of adenosine triphosphate and the anabolic precursors needed for survival, growth and motility. The recent observations that mutant oncogenic proteins and the loss of tumor suppressors activate key metabolic enzymes suggest that selective inhibition of these enzymes may yield effective cancer therapeutics with acceptable toxicities. In support of this concept, pre-clinical studies of small molecule antagonists of several metabolic enzymes in tumor-bearing mice have demonstrated reasonable therapeutic indices. We will review the rationale for targeting metabolic enzymes as a strategy to treat cancer and will detail the results of several recent clinical trials of metabolic inhibitors in advanced cancer patients.
  • |*Drug Design [MESH]
  • |*Molecular Targeted Therapy/trends [MESH]
  • |Antineoplastic Agents/*pharmacology/*therapeutic use [MESH]
  • |Biomarkers, Tumor/metabolism [MESH]
  • |Cell Proliferation/drug effects [MESH]
  • |Cell Transformation, Neoplastic/drug effects [MESH]
  • |Energy Metabolism/drug effects [MESH]
  • |Gene Expression Regulation, Neoplastic/drug effects [MESH]
  • |Humans [MESH]
  • |Neoplasms/*drug therapy/enzymology/*metabolism [MESH]
  • |Oxidative Phosphorylation/drug effects [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box